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of these covariates is oft en imprecise, thus 
leaving substantial residual confounding. 
For example, in the study by Becker et al.,7 
the mean estimated glomerular fi ltration 
rate was 63 ml per minute and the mean 
ADPN 6 µmol per liter, compared with 
32 ml per minute and 12 µmol per liter in 
the study by Menon et al.8 Th e much lower 
ADPN in the fi rst of the two studies clearly 
reflects less severe renal insufficiency. 
Given the close association between ADPN 
and renal function, the direct relationship 
between ADPN and mortality in the study 
by Menon et al.8 may be due to residual 
confounding attributable to reduced renal 
function and/or to confounding by proc-
esses that accompany chronic renal diseases 
that are not captured by adjustment for the 
glomerular fi ltration rate. Furthermore, 
diff erential retention of high-molecular 
weight forms of ADPN in renal failure,9 the 
nutritional and infl ammatory status, poly-
morphisms in the gene encoding ADPN, 
and the various possibilities of combina-
tion of these factors may substantially alter 
the expected (inverse) relationship between 
ADPN and clinical outcomes (Figure 1). 
Causality assessment is a complex proc-
ess, and epidemiologic associations per se 
rarely if ever allow defi nitive conclusions 
on causality. Biological experiments and 
randomized experimental studies in ani-
mal models and in humans are needed to 
frame a reliable interpretation of such asso-
ciations. Yet the study by Kollerits et al.1 
is a very intriguing hypothesis-generating 
exercise, because, in a context where ADPN 
manifested its insulin-sensitizing and car-
diovasculo-protective properties (Becker 
et al.’s analysis in the same database7), it 
also displayed a clear-cut direct associa-
tion with a faster rate of renal disease pro-
gression. Th is is noteworthy because, in 
general, cardiovascular and renal damage 
proceed in parallel in patients with CKD. 
To explain their counterintuitive fi ndings, 
Kollerits et al.1 advance the hypothesis that 
in men with CKD there may be a condition 
of resistance to ADPN. However, because 
in this same cohort high ADPN was asso-
ciated with a lower incident cardiovascu-
lar risk,7 this hypothesis would imply that 
ADPN resistance in CKD patients is con-
fi ned to the kidney. Medical research dur-
ing the past century has been a to-and-fro 
process, from the bench to the bedside and 
vice versa. Given the therapeutic potential 
of increasing ADPN by pharmacologic 
intervention, the defi nition of the nature 
of the relationship between ADPN and 
progression of renal disease is a worthy 
scientifi c question. Th e precise defi nition 
of this association now requires that the 
research focus be moved to the experimen-
tal laboratory.
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Malignancy after kidney 
transplantation: Still a challenge
J-L Bosmans1 and GA Verpooten1
Long-term complications of continuous immunosuppression still remain 
a serious threat and are currently drawing the attention of transplant 
physicians. Wimmer et al. show that malignancy occurs approximately 
fourfold more frequently in renal-transplant recipients than in a normal 
control population.  Besides immunosuppression, viruses probably play 
an important oncogenic role in transplant recipients. The retrospective 
analysis by Wimmer et al. suggests that mTOR inhibitors and interleukin-2 
receptor antibodies are promising immunosuppressive drugs to reduce 
the risk of cancer after transplantation.  These preliminary results must be 
confirmed in large, prospective, randomized, controlled trials, with long 
follow-up, designed to evaluate the incidence of de novo malignancy in 
transplant recipients.
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Tremendous progress has been made in 
the fi eld of clinical transplantation since 
the fi rst kidney transplantation was per-
formed in 1954.1 Still, transplant physi-
cians are continually coping with the 
delicate balance between optimizing graft  
survival and reducing the side eff ects of 
immunosuppressive drugs, such as infec-
tions, malignancy, nephrotoxicity, and 
cardiovascular morbidity and mortality 
(Figure 1).
With the introduction of cyclosporine 
in the early 1980s, and tacrolimus, myco-
phenolate, interleukin-2 (IL-2) receptor 
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blockers, and sirolimus in the 1990s, the 
rate of acute rejection within the first 
year could be progressively reduced to 
almost 10%, and 1-year kidney graft 
survival improved to more than 90%. 
These encouraging short-term results 
urged physicians to focus their attention 
on long-term complications related to 
chronic immunosuppression.
Wimmer, Rentsch, and colleagues2 (this 
issue) report on the incidence of de novo 
malignancies in 2419 renal-transplant 
recipients at one institution between 1978 
and 2005. Th is outstanding analysis of a 
single-center database probably provides 
more accurate information than registry-
based studies, which are oft en fl awed by 
inherent limitations and incomplete fol-
low-up.
In this retrospective study, renal-trans-
plant recipients had a 4.3 times higher 
risk of developing any type of cancer, 
compared with an age- and sex-matched 
population of the same geographical area.2 
Similar markedly increased risk of cancer 
aft er renal transplantation was recently 
reported in an Australian3 and a French4 
population, thereby confi rming the mag-
nitude of the problem.
Vajdic et al.3 compared the standard-
ized incidence ratios (SIDs) for cancer 
in patients with end-stage renal disease 
before renal replacement therapy (SID = 
1.16), in dialysis patients (SID = 1.35), and 
in renal-transplant recipients (SID = 3.27). 
Th eir data clearly demonstrate that the risk 
for cancer is only slightly increased before 
transplantation but increases almost three-
fold aft er transplantation, providing strong 
evidence that immunosuppression plays 
an important role in the development of 
cancer aft er renal transplantation.
Interestingly, Wimmer et al.2 observed 
a dramatically increased risk for some 
specifi c cancers aft er kidney transplanta-
tion, namely Kaposi’s sarcoma, skin can-
cer, kidney cancer, oropharyngeal cancers, 
and lymphoproliferative disorders. Many 
of these cancers are associated with infec-
tion by oncogenic viruses, such as human 
papilloma virus (in the case of skin and 
cervical cancers), Epstein-Barr virus (in 
the case of lymphoproliferative disor-
ders), and human herpesvirus 8 (in the 
case of Kaposi’s sarcoma). In contrast, the 
authors found only a twofold increased 
incidence in renal-transplant recipients 
for some of the most common tumors in 
the general population — colorectal, lung, 
prostate, and breast cancer. Such data 
support the hypothesis that immunosup-
pression is rarely the only culprit for the 
increased incidence of malignancy aft er 
transplantation but rather plays a per-
missive role in the development of virus-
induced tumors. In addition, acquired 
cystic kidney disease may likely explain 
the increased incidence of kidney cancer 
aft er renal transplantation.
However, the crucial question that needs 
to be addressed in the fi eld of transplanta-
tion remains: Can we reduce the incidence 
of malignancy in transplant recipients, 
while still maintaining adequate immu-
nosuppression? In their retrospective 
analysis, Wimmer et al.2 attempted to 
address this issue. Th e authors investi-
gated the impact of the initial immuno-
suppressive regimen (around 3 weeks 
aft er transplantation, at the time of dis-
charge) on the subsequent development 
of malignancy. However, this approach 
has important limitations, as it does not 
take into account the subsequent changes 
in immunosuppressive regimen, which 
may have infl uenced the occurrence of 
de novo malignancies. In addition, in this 
study, the group of patients, treated with 
mammalian target of rapamycin (mTOR) 
and IL-2 receptor antagonists, was small 
and had a short period of follow-up. Th e 
results of this statistical analysis therefore 
need to be interpreted cautiously and 
should encourage transplant physicians 
to undertake long-term prospective, ran-
domized and controlled clinical trials 
addressing this issue.
Despite these limitations, the data pro-
vided by Wimmer et al.2 strongly suggest 
that two classes of immunosuppressive 
drugs may have the potential to reduce 
malignancy aft er transplantation. Accord-
ing to their study, mTOR inhibitor-based 
therapies show a clear trend toward a 
lower tumor risk (both overall and skin 
cancer) as compared with all other immu-
nosuppressive regimens. Several clinical 
trials in renal-transplant recipients have 
confi rmed the signifi cantly reduced risk of 
developing any malignancy under treat-
ment with mTOR inhibitors.5–7 In these 
studies, with median follow-up between 
963 days and 5 years, mTOR inhibitors 
not only reduced the relative risk of any 
de novo cancer by almost 60% but also 
delayed the first presentation of these 
tumors. In addition, Stallone, Schena, and 
colleagues8 observed in 15 kidney trans-
plant recipients that sirolimus induces 
remission of dermal Kaposi’s sarcoma 
within 6 months, while providing ade-
quate immunosuppression.
Wimmer et al.2 also observed that IL-2 
receptor antibodies signifi cantly reduce the 
incidence of post-transplant lymphoprolif-
erative disease, as compared with depleting 
antibodies, such as ATG, ALG, or OKT3. 
Similar conclusions were reached by 
Cherikh et al.,9 who compared the actual 
incidence of post-transplant lymphopro-
liferative disease in 38 519 primary kid-
ney transplant recipients according to the 
induction therapy (monoclonal, polyclonal, 
or IL-2 receptor antibodies or no induction 
Figure 1 | Immunosuppression: a delicate balance.
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therapy). In this study, the actual incidence 
of post-transplant lymphoproliferative dis-
ease was similar in patients treated with IL-
2 receptor antibodies versus patients who 
received no induction therapy but was 
signifi cantly lower in these groups than in 
patients who received depleting antibodies 
as induction treatment.
Whether mycophenolate mofetil 
(MMF) may reduce the risk of cancer is 
currently unclear. Although the analysis 
by Wimmer et al.2 suggests that MMF 
may even enhance the risk of cancer, 
when combined with calcineurin inhibi-
tors, this conclusion could be biased by 
the retrospective design of their study and 
the preferential assignment of MMF to 
older recipients. Robson et al.10 prospec-
tively examined the risk of lymphoma and 
other malignancies in 6751 de novo renal-
transplant recipients treated with MMF 
and observed a similar risk at 3 years in 
comparison with an equal number of 
matched controls receiving non-MMF-
based immunosuppression.
Obviously, malignancy is still a challeng-
ing complication of long-term immuno-
suppression. Immunosuppressive drugs, 
such as mTOR inhibitors and IL-2 recep-
tor antibodies, probably reduce the risk for 
all or some specifi c malignancies and are 
currently tested in clinical trials designed 
to reduce the incidence of some specifi c 
cancers in kidney transplant recipients.
Achieving tolerance, the Holy Grail for 
transplant physicians, would undoubtedly 
obviate the need for lifelong immunosup-
pression and its associated complications. 
Pilot clinical trials are currently running to 
explore the biology of tolerance in humans 
and will hopefully shed more light on the 
feasibility of this goal in the future.
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Diabetic nephropathy and 
proximal tubule ROS: Challenging 
our glomerulocentricity
SP Bagby1
Diabetic nephropathy is currently viewed as a predominantly 
glomerular process with glomerular injury driving secondary tubular 
loss. Brezniceanu and colleagues apply transgenic methods to support 
a prominent role for reactive oxygen species as mediators and for the 
proximal tubule as a major site of early disease activity in diabetes. 
Results support evidence for early tubular apoptosis and atrophy in 
human diabetic nephropathy.
Kidney International (2007) 71, 1199–1202. doi:10.1038/sj.ki.5002286 
Diabetic nephropathy has long been 
considered virtually synonymous with 
glomerulosclerosis, the latter viewed as 
the cardinal manifestation and primary 
lesion of this functionally devastating 
disease. Recent gentle challenges to our 
collective dogmatism on this topic have 
emerged, but the paper by Brezniceanu 
and colleagues1 (this issue) takes a giant 
step toward shift ing the glomerulo-tubu-
lar balance in the fi eld. Th ese authors have 
made elegant use of transgenic technol-
ogy to achieve selective overexpression of 
catalase in the renal proximal tubular epi-
thelial cell (RPTC). Catalase, an enzyme 
that breaks down H2O2 to inactive com-
ponents, is used as a tool to reduce gen-
eration of reactive oxygen species (ROS) 
and thereby probe their function. Using 
the RPTC-specifi c, androgen-regulated 
KAP promoter to drive transgenic cata-
lase expression, Brezniceanu and col-
leagues1 found that adult males exhibited 
spontaneous overexpression of catalase 
protein and activity in RPTCs, without 
the addition of exogenous androgen. Th e 
investigators accordingly used the wild-
type and transgenic adult male mice to 
examine the role of ROS in early strepto-
zotocin (STZ)-induced diabetic nephrop-
athy, specifi cally asking whether limiting 
ROS generation attenuates selected dia-
betes-induced abnormalities in the prox-
imal tubule: increased angiotensinogen 
(Agt), plasminogen activator inhibitor-1, 
apoptosis, and histologic injury following 
2 weeks of diabetes.
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